MSC 2015103B

Drug Profile

MSC 2015103B

Alternative Names: AS703988; MSC2015103B

Latest Information Update: 16 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Serono
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (PO)
  • 01 Sep 2011 Phase-I clinical trials in Solid tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top